RT Journal Article SR Electronic T1 Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 1049 OP 1055 VO 299 IS 3 A1 Ulrich Russ A1 Ulf Lange A1 Cornelia Löffler-Walz A1 Annette Hambrock A1 Ulrich Quast YR 2001 UL http://jpet.aspetjournals.org/content/299/3/1049.abstract AB The novel sulfonylthiourea 1-[[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl]-3-methylthiourea (HMR 1883), a blocker of ATP-sensitive K+channels (KATP channels), has potential against ischemia-induced arrhythmias. Here, the interaction of HMR 1883 with sulfonylurea receptor (SUR) subtypes and recombinant KATPchannels is compared with that of the standard sulfonylurea, glibenclamide, in radioligand receptor binding and electrophysiological experiments. HMR 1883 and glibenclamide inhibited [3H]glibenclamide binding to SUR1 withKi values of 63 μM and 1.5 nM, and [3H]opener binding to SUR2A/2B withKi values of 14/44 μM and 0.5/2.8 μM, respectively (values at 1 mM MgATP). The interaction of HMR 1883 with the SUR2 subtypes was more sensitive to inhibition by MgATP and MgADP than that of glibenclamide. In inside-out patches and in the absence of nucleotides, HMR 1883 inhibited the recombinant KATPchannels from heart (Kir6.2/SUR2A) and nonvascular smooth muscle (Kir6.2/SUR2B) with IC50 values of 0.38 and 1.2 μM, respectively; glibenclamide did not discriminate between these channels (IC50 ∼ 0.026 μM). In whole cells, the recombinant vascular KATP channel, Kir6.1/SUR2B, was inhibited by HMR 1883 and glibenclamide with IC50 values of 5.3 and 0.043 μM, respectively. The data show that the sulfonylthiourea exhibits a selectivity profile quite different from that of glibenclamide with a major loss of affinity toward SUR1 and slight preference for SUR2A. The stronger inhibition by nucleotides of HMR 1883 binding to SUR2 (as compared with glibenclamide) makes the sulfonylthiourea an interesting tool for further investigation. The American Society for Pharmacology and Experimental Therapeutics